ORTHOVISC®

TEXT SIZE  

Decrease Font SizeReset Font SizeIncrease Font Size

Managed Care and Reimbursement Support Services

 

Physician Locator

Help patients locate you. Sign up to be
listed in the physician locator now.

        CLICK HERE >>

Patient Education Seminars

Learn more about patient
education seminars.
        CLICK HERE >>

HCPCS Code J7324

For additional claim code information
CLICK HERE >>

    Reimbursement Information

     
    United Healthcare updates protocol on acquisition for administration of sodium hyaluronate preparations,
    effective April 1, 2010. ORTHOVISC® High Molecular Weight Hyaluronan remains an approved HA product for buy and bill.     

    Click here to view UHC Administrative Guide 2010

    Please contact your ORTHOVISC® Representative for more information. 

    ORTHOVISC® is eligible for reimbursement by Medicare and most managed care plans. Depending upon reimbursement coverage, ORTHOVISC® can be obtained by purchasing directly from DePuy Mitek Customer Service at 1-800-842-4682 or writing an ORTHOVISC® prescription. Insurance policies and coverage for ORTHOVISC® vary patient to patient and plan to plan. It is recommended to check with a specific patient insurance carrier to verify coverage. If you have questions about ORTHOVISC® Medicare or Private Pay Insurance coverage, contact ORTHOVISC®Line, our reimbursement support hotline, at 1-866-633-VISC (8472).

     

    The reimbursement information contained in this web site is provided for informational purposes only and represents no statement, promise, or guarantee by DePuy Mitek, Inc. concerning levels of reimbursement, payment, or charge. Similarly, all CPT and HCPCS codes are supplied for informational purposes only and represent no statement, promise, or guarantee by DePuy Mitek, Inc. that these codes will be appropriate or reimbursement will be made. The information presented is not intended to increase or maximize reimbursement by any payor. We strongly recommend that you consult your payor organization with regard to its reimbursement policies.

     

    JCode Source: Federal Register/Vol.72, No. 227,pp 66774/Tuesday, November 27, 2007. All Current Procedural Terminology (CPT) five-digit numeric codes, descriptions, numeric modifiers, instructions, guidelines, and other material are Copyright 2007 American Medical Association. All Rights Reserved.

    ICD-9 is based on the official version of the World Health Organization's Ninth Revision, International Classification of Diseases.

    CPT codes and descriptions only are Copyright 2007 American Medical Association. All Rights Reserved.

     
    EMAIL THIS PAGEEMAIL THIS PAGE         PRINT PAGEPRINT PAGE

    This site is published by DePuy Mitek, Inc., which is solely responsible for its contents.
    It is intended for healthcare professionals in the U.S. and contains U.S. based product information only.
    ORTHOVISC® is manufactured by and is a registered trademark of Anika Therapeutics, Inc. Distributed by DePuy Mitek, Inc.

    © DePuy Mitek, Inc. 2005 - 2010

    AN OFFICIAL HEALTH AND FITNESS PROVIDER

    Important Safety Information

    ORTHOVISC® is indicated in the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and to simple analgesics, e.g. acetaminophen. In clinical studies, the most commonly reported adverse events were arthralgia, back pain, and headache. Other side effects included local injection site adverse events.

    ORTHOVISC® is contraindicated in patients with known hypersensitivity to hyaluronate formulations or known hypersensitivity (allergy) to gram positive bacterial proteins. ORTHOVISC® should not be injected in patients with infections or skin diseases in the area of the injection site or joint. Strict aseptic technique should be used. The effectiveness of more than 1 course has not been established.